http://www.igenericdrugs.com Review Rating: 100 out of 100 based on 386 reviews. 386 stars
Generic drugs
List of interchangeable brand and generic drugs
compare generic drug prices
 

Enbrel

Search a suitable generic or branded drugs, if you could not find the prescribed medicine. This site does not supply any medicines. It contains prices for information purposes only.
You should consult a doctor about the dosage before using this medicine!

DRUG NAME:     

 

Enbrel uses and description

Sort by popularity
Enbrel - Used in the treatment of rheumatoid arthritis and the reduction of the adverse effects of tumor necrosis factor (TNF). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated levels of TNF are found in tissues and fluids of patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (AS), and plaque psoriasis. Enbrel (Immunex Corp) binds specifically to tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors.

Indication: For treatment of severe adult and juvenille rheumatoid arthritis

Enbrel works by decreasing a certain protein produced by the immune system. The immune system helps the body fight infections. In people with autoimmune disorders, the immune system mistakes the body's own cells for invaders and attacks them.

Enbrel is used to treat the symptoms of rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, and to prevent joint damage caused by these conditions. It is also used to treat plaque psoriasis in adults and polyarticular juvenile idiopathic arthritis in children who are at least 2 years old.

Enbrel is not a cure for any autoimmune disorder and will only treat the symptoms of your condition.

Enbrel may also be used for other purposes not listed in this medication guide.

Used alone or in combination with methotrexate for the treatment of active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. Treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. In patients with rheumatoid arthritis, Enbrel used alone or in combination with methotrexate has been shown to slow progression of disease-associated structural damage as measured by x-ray. Treatment of active polyarticular-course juvenile chronic arthritis in children 4-17 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA (see Pharmacodynamics under Actions).

Adults with Rheumatoid Arthritis: Treatment of signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis. In combination with methotrexate in patients who do not respond adequately to methotrexate alone. Pediatric Patients with Juvenile Idiopathic Arthritis: Treatment of active polyarticular-course juvenile chronic arthritis in children 4-17 years who have had an inadequate response to, or who have proved intolerant of methotrexate. Enbrel has not been studied in children <4 years. Adults with Psoriatic Arthritis: Reduction of signs and symptoms of active arthritis in adult patients with psoriatic arthritis. In combination with methotrexate in patients who do not respond adequately to methotrexate alone. Adults with Ankylosing Spondylitis: Treatment of signs and symptoms of active ankylosing spondylitis in adults who have had an inadequate response to conventional therapy. Adults with Plaque Psoriasis: Treatment of adults with moderate to severe chronic plaque psoriasis who failed to respond to, or who have contraindications to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA.

Treatment of active RA in adults when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate (unless contraindicated), has been inadequate. Enbrel has been shown to halt disease-associated structural damage when used in combination with methotrexate. Treatment of severe, active and progressive RA in adults not previously treated with methotrexate. In patients with RA, Enbrel used alone or in combination with methotrexate has been shown to slow the progression of disease-associated structural damage as measured by x-ray. Treatment of active polyarticular-course juvenile chronic arthritis in children 4-17 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Enbrel has not been studied in children <4 years. Treatment of active and progressive psoriatic arthritis in adults when the response to previous DMARDs therapy has been inadequate. Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to previous DMARDs therapy. Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA (see Pharmacology under Actions).

Indications: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis

Indications: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis

Treatment of signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis. Enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. Treatment of active polyarticular-course juvenile chronic arthritis in children 4-17 years who have had an inadequate response to, or who have proved intolerant of methotrexate. Enbrel has not been studied in children <4 years. Enbrel is indicated for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis. Enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. Treatment of active ankylosing spondylitis in adults. Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA (see Pharmacology under Actions).

For reducing signs and symptoms, and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. For reducing signs and symptoms of moderately to severely active polyarticular-course juvenile idiopathic arthritis (JIA) in patients who have had an inadequate response to one or more DMARDs. For reducing signs and symptoms of active psoriatic arthritis in patients with psoriatic arthritis. Enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. For reducing signs and symptoms in patient with active ankylosing spondylitis. Treatment of adults (≥18 years) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 8 years who are inadequately controlled by, or intolerant to, other systemic therapies or phototherapies.

Enbrel, an immunomodulating anti-TNF-alpha biologic, is indicated for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis (PsA), ankylosing spondylitis (AS) and plaque psoriasis (PsO). Enbrel can be prescribed either as a monotherapy or as a combined therapy with methotrexate.

Active ingredients: Etanercept
Unit description, dosagePrice, USD
Injectable; Injection; Etanercept 25 mg / ml
Injectable; Injection; Etanercept 50 mg / ml
Enbrel (pre-filled syringe) 25 mg/0.5 mL x 4's$ 865.34
Enbrel 50 mg/1 mL x 4's
Enbrel 25 mg x 4's
Enbrel (vial) 25 mg x 4's
Enbrel (pre-filled syringe) 25 mg x 4's
Enbrel (pre-filled syringe) 50 mg x 4's
Enbrel (+ prefilled syringe) 25 mg x 4's
Enbrel 50 mg x 4's
50 mg x 1 mL x 1's$ 291.86
25 mg x 0.5 mL x 1's$ 147.84
Enbrel 25 mg x 1 oáng etanercept, 1 oáng tieâm, 1 kim tieâm, 1 boä phaän ñieàu chænh, 2 boâng taåm alcol
Enbrel (syringe) 25 mg x 2's
Enbrel (syringe) 50 mg x 2's
Enbrel 50mg x 1mL INJ / 0.5ml$ 147.84
Enbrel 50mg x 1mL INJ / 1ml$ 291.86
Enbrel 25mg x 0.5mL INJ / 0.5ml$ 147.84

List of enbrel brand and generic drugs

Enbrel (Immunex Corp)
Enbrel 25 mg powder and solvent for solution for injection (United Kingdom)
Enbrel 25mg / ml powder and solvent for solution for injection for paediatric use (United Kingdom)
Enbrel 25mg solution for injection in pre-filled syringe (United Kingdom)
Enbrel 50 mg solution for injection in pre-filled pen (United Kingdom)
Enbrel 50 mg solution for injection in pre-filled syringe (United Kingdom)
ENBREL INJ.
ENBREL INJ. Injection / 25mg (1 vial units)$ 167.88
Enbrel Junior (Switzerland)
Injectable; Injection; Etanercept 25 mg / 0.5 ml
Injectable; Injection; Etanercept 50 mg / ml
Enbrel Lyfjaver (Iceland)
Enbrel Myclic (Germany)
Enbrel Pédiatrie (Belgium)
Enbrel Pre-Filled Pen/Enbrel Pre-Filled Syringe (Hongkong)
Enbrel Pre-Filled Pen/Enbrel Pre-Filled Syringe 50 mg x 4's
Enbrel Pre-Filled Pen/Enbrel Pre-Filled Syringe 25 mg x 4's
Enbrel Vial (Hongkong)
Enbrel Vial 25 mg x 4's
ENBROL (India)
25 mg x 1's$ 167.86
Enbrol 25mg INJ / 1ml$ 167.86
Etanar (Colombia)
Etanercept (Belgium)
Yisaipu (China)
 
Privacy Policy
© 2003 - 2014 igenericdrugs.com All Rights Reserved
 
Disclamer